Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Association Between Longitudinal Changes in TRACP-5b and Bone Metastasis Progression During Osimertinib Therapy.

Anticancer research - 1 Jun 2026

Ikegami Keisuke, Makihara Reiko Ando, Shinno Yuki, Tateishi Akiko, Mizutani Tomonori, Okuma Yusuke, Yoshida Tatsuya, Horinouchi Hidehito, Yamamoto Noboru, Hashimoto Hironobu, Hori Satoko, Goto Yasushi

Abstract excerpt

BACKGROUND/AIM: Bone metastases (BMs) of non-small cell lung cancer (NSCLC) are associated with skeletal-related events that impair quality of life. Tartrate-resistant acid phosphatase 5b (TRACP-5b) is considered a marker of osteoclastic activity; however, its prognostic utility for NSCLC patients with BMs remains unclear. This study aimed to evaluate the association between longitudinal changes in TRACP-5b and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Neoplasms

Share to Carcinoma, Non-Small-Cell Lung

Share to Indoles

Share to Longitudinal Studies

Share to Pyrimidines

Share to Tartrate-Resistant Acid Phosphatase

Source

Identifiers

PMID: 42203350
DOI: 10.21873/anticanres.18205

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

The Association Between Longitudinal Changes in TRACP-5b and Bone Metastasis Progression During Osimertinib Therapy.PMID 42203350Read ↗

Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib.Semantic proximity Read ↗

Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy.Semantic proximity Read ↗

The Effect of Bone-Modifying Agents on Post-Bone Metastasis SurvivalSemantic proximity Read ↗

Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical ApplicationsSemantic proximity Read ↗

[Impact of bone metastasis on the prognosis of lung adenocarcinoma patients treated with third-generation EGFR-TKI and the underlying mechanisms].Semantic proximity Read ↗

Activating <i>RET</i> Mutations Promotes Osteoblastic Bone Metastases in Medullary Thyroid CancerSemantic proximity Read ↗

Relationship between clinical features and gene mutations in non-small cell lung cancer with osteoblastic bone metastasis.Semantic proximity Read ↗

Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC.Semantic proximity Read ↗

Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs.Semantic proximity Read ↗

Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.Semantic proximity Read ↗

Bone Scan Index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.